Revenue
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | £6.0M | £4.0M | £4.0M | £27.2M |
| Operating expenses | £21.9M | £30.7M | £29.2M | £43.9M |
| Operating income | −£19.5M | −£28.8M | −£26.9M | −£30.7M |
| Operating margin | −325.00% | −720.00% | −672.50% | −112.87% |
| EBITDA | −£16.2M | −£26.1M | −£22.8M | −£27.5M |
| EBITDA margin | −270.00% | −652.50% | −570.00% | −101.10% |
| Net income | £5.3M | −£28.7M | −£21.7M | −£26.9M |
| Net profit margin | 88.33% | −717.50% | −542.50% | −98.90% |
| Basic EPSper basic share | £0.01 | -£0.08 | -£0.07 | -£0.14 |
| Diluted EPSper diluted share | £0.01 | -£0.08 | -£0.07 | -£0.14 |
Reported major voting-rights holders
| Holder | Voting rights |
|---|---|
M&G Plc | 12.02%Sep 11, 2025 · 49.58M votes |
Liontrust Investment Partners LLP | 7.29%Jul 31, 2026 · 32.72M votes |
Development Bank of Wales PLC | 2.92%May 28, 2026 · 13.13M votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Creo Medical ($CREO) increased first-half revenue to £3.2 million from £2.2 million and reduced its underlying continuing operating loss to £4.9 million from £6.7 million. Underlying operating costs fell 15% to £7.9 million as the surgical- ...